公开(公告)号：US20160090418A1

公开(公告)日：2016-03-31

申请号：US14965301

申请日：2015-12-10

申请人： Merrimack Pharmaceuticals, Inc.

发明人： Bambang ADIWIJAYA ,  Akos CZIBERE ,  William KUBASEK ,  Gavin MACBEATH ,  Sharon MOULIS ,  Rachel C. NERING ,  Lin NIE ,  Defne YARAR

IPC分类号： C07K16/28 ,  C07K16/30 ,  C12Q1/68

CPC分类号： C07K16/2863 ,  A61K31/337 ,  A61K39/3955 ,  C07K16/3015 ,  C07K16/3023 ,  C07K16/3069 ,  C07K2317/21 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/565 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/112 ,  C12Q2600/158 ,  G01N33/574 ,  G01N2333/71 ,  G01N2800/52

摘要： Provided are methods for optimizing therapy of, treating a patient having, or selecting (identifying) patients who will benefit from treatment for, a cancer (e.g., a non-hematological cancer; e.g., a gynecological cancer). The methods comprise determining whether the patient will benefit from treatment with an ErbB3 inhibitor (e.g., an anti-ErbB3 antibody), with or without either a taxane or an aromatase inhibitor, or with a taxane or an aromatase inhibitor in the absence of an ErbB3 inhibitor, based on levels of particular biomarkers and combinations of biomarkers measured in a biological sample obtained from the patient. The methods further comprise optimizing the patient's therapy, selecting the patient for treatment, or treating the patient accordingly. In various aspects the biological samples are sections of a biopsy (e.g., a formalin fixed paraffin embedded biopsy). In other aspects the biomarkers are proteins and/or nucleic acids. In other aspects the biomarkers function in ErbB-mediated signal transduction.

摘要翻译： 提供了用于优化治疗患者的方法，所述治疗具有或选择（鉴定）将从癌症（例如，非血液癌症例如妇科癌症）治疗中受益的患者。 所述方法包括确定在不存在ErbB3的情况下，是否使用具有或不含紫杉烷或芳香酶抑制剂的ErbB3抑制剂（例如，抗ErbB3抗体）或使用紫杉烷或芳香酶抑制剂治疗患者 抑制剂，基于从患者获得的生物样品中测量的特定生物标志物的水平和生物标志物的组合。 所述方法还包括优化患者的治疗，选择患者进行治疗或相应地治疗患者。 在各个方面，生物样品是活检的切片（例如，福尔马林固定石蜡包埋的活检）。 在其它方面，生物标志物是蛋白质和/或核酸。 在其他方面，生物标志物在ErbB介导的信号转导中起作用。

公开(公告)号：US20170210810A1

公开(公告)日：2017-07-27

申请号：US15386723

申请日：2016-12-21

申请人： Merrimack Pharmaceuticals, Inc.

发明人： Bambang ADIWIJAYA ,  Akos CZIBERE ,  William KUBASEK ,  Gavin MACBEATH ,  Sharon MOULIS ,  Rachel C. NERING ,  Lin NIE ,  Defne YARAR

IPC分类号： C07K16/28 ,  A61K39/395 ,  C12Q1/68 ,  A61K31/337

CPC分类号： C07K16/2863 ,  A61K31/337 ,  A61K39/3955 ,  C07K16/3015 ,  C07K16/3023 ,  C07K16/3069 ,  C07K2317/21 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/565 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/112 ,  C12Q2600/158 ,  G01N33/574 ,  G01N2333/71 ,  G01N2800/52

摘要： Provided are methods for optimizing therapy of, treating a patient having, or selecting (identifying) patients who will benefit from treatment for, a cancer (e.g., a non-hematological cancer; e.g., a gynecological cancer). The methods comprise determining whether the patient will benefit from treatment with an ErbB3 inhibitor (e.g., an anti-ErbB3 antibody), with or without either a taxane or an aromatase inhibitor, or with a taxane or an aromatase inhibitor in the absence of an ErbB3 inhibitor, based on levels of particular biomarkers and combinations of biomarkers measured in a biological sample obtained from the patient. The methods further comprise optimizing the patient's therapy, selecting the patient for treatment, or treating the patient accordingly. In various aspects the biological samples are sections of a biopsy (e.g., a formalin fixed paraffin embedded biopsy). In other aspects the biomarkers are proteins and/or nucleic acids. In other aspects the biomarkers function in ErbB-mediated signal transduction.

公开(公告)号：US20170267767A1

公开(公告)日：2017-09-21

申请号：US15601955

申请日：2017-05-22

申请人： Merrimack Pharmaceuticals, Inc.

发明人： Bambang ADIWIJAYA ,  Akos CZIBERE ,  William KUBASEK ,  Gavin MACBEATH ,  Sharon MOULIS ,  Rachel C. NERING ,  Lin NIE ,  Defne YARAR

IPC分类号： C07K16/28 ,  C12Q1/68 ,  C07K16/30 ,  G01N33/574

CPC分类号： C07K16/2863 ,  A61K31/337 ,  A61K39/3955 ,  C07K16/3015 ,  C07K16/3023 ,  C07K16/3069 ,  C07K2317/21 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/565 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/112 ,  C12Q2600/158 ,  G01N33/574 ,  G01N2333/71 ,  G01N2800/52

摘要： Provided are methods for optimizing therapy of, treating a patient having, or selecting (identifying) patients who will benefit from treatment for, a cancer (e.g., a non-hematological cancer; e.g., a gynecological cancer). The methods comprise determining whether the patient will benefit from treatment with an ErbB3 inhibitor (e.g., an anti-ErbB3 antibody), with or without either a taxane or an aromatase inhibitor, or with a taxane or an aromatase inhibitor in the absence of an ErbB3 inhibitor, based on levels of particular biomarkers and combinations of biomarkers measured in a biological sample obtained from the patient. The methods further comprise optimizing the patient's therapy, selecting the patient for treatment, or treating the patient accordingly. In various aspects the biological samples are sections of a biopsy (e.g., a formalin fixed paraffin embedded biopsy). In other aspects the biomarkers are proteins and/or nucleic acids. In other aspects the biomarkers function in ErbB-mediated signal transduction.

公开(公告)号：US20160303232A1

公开(公告)日：2016-10-20

申请号：US15156603

申请日：2016-05-17

申请人： Merrimack Pharmaceuticals, Inc.

发明人： Bambang ADIWIJAYA ,  Akos Czibere ,  Rachel C. Nering ,  Gavin Macbeath

IPC分类号： A61K39/395 ,  A61K31/519 ,  C07K16/28 ,  A61K31/337 ,  A61K9/00

CPC分类号： A61K39/39558 ,  A61K9/0019 ,  A61K31/337 ,  A61K31/519 ,  A61K2039/505 ,  A61K2039/545 ,  C07K16/2863 ,  C07K16/32 ,  C07K2317/21 ,  A61K2300/00

摘要： Compositions and methods for treating a cancer in a selected human patient are provided, comprising administering to the patient a combination of an anti-ErbB3 antibody (e.g., Seribantumab) and a second anti-cancer therapeutic. A cancer to be treated by the methods and compositions disclosed herein includes cancers that are heregulin (HRG) positive cancers.

摘要翻译： 提供了用于治疗所选择的人类患者中的癌症的组合物和方法，包括向患者施用抗ErbB3抗体（例如，血清白蛋白抗体）和第二抗癌治疗剂的组合。 通过本文公开的方法和组合物治疗的癌症包括作为胰岛素（HRG）阳性癌症的癌症。